ReviewBrain sciences2023
A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia.
Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- A meta-analysis and systematic review of creativity in schizophrenia: toward an ecological understanding integrating clinical and philosophical perspectives.Frontiers in psychology · 2026Pooled it
- The effects of positive psychology theory in the rehabilitation nursing of Chinese patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2025Pooled it
- Quality of life in schizophrenia: Symptomatic markers of improvement over time.Psychiatric rehabilitation journal · 2026Trial
- Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia.Actas espanolas de psiquiatria · 2025Trial
- Hydrogel-Based Depot Systems in Psychiatric Pharmacotherapy: A Narrative Review Rethinking Long-Acting Drug Delivery.Gels (Basel, Switzerland) · 2026Review
- Quality of life, disability and antipsychotics-related side effects in schizophrenia spectrum and bipolar disorder: the role of patient-reported outcome measures.European archives of psychiatry and clinical neuroscience · 2026Article
- Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia.Human psychopharmacology · 2026Article
- Treatment Adherence and Health Care Utilization After a First Episode of Psychosis.JAMA network open · 2026Article
- Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISMJournal of clinical medicine · 2026Review
- Real-world antipsychotic prescribing patterns and mortality in schizophrenia: a registry cohort study from China.Epidemiology and psychiatric sciences · 2026Article
- Dissociation between the dynamics of symptom scores and network metrics in psychosis treatment: a proof-of-concept study using network intervention analysis.Psychopharmacology · 2026Article
- Analysis of the Influencing Factors of Aripiprazole and Risperidone on Bone Mass Health in Patients with Chronic Schizophrenia: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2026Article
- A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.Schizophrenia bulletin open · 2026Article
- Cross-Sectional Associations of Insomnia, Social Dysfunction, Suicidality, and Depressive Symptoms in Rural Adults with Schizophrenia: A Sex-Stratified Analysis.Neuropsychiatric disease and treatment · 2026Article
- Adaptation of the "Osnabrück Scale for Therapy Adjustment and Identification of Psychological Complaints in Schizophrenia-OSSTI-TR" into Turkish culture and investigation of its psychometric characteristics.Frontiers in psychiatry · 2026Article
- Health-Related Quality of Life Among Patients with Treatment-Resistant Schizophrenia Receiving Clozapine-Based Therapy in South Kalimantan, Indonesia.Patient preference and adherence · 2026Article
- Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.International clinical psychopharmacology · 2025Review
- Driving Performance in Schizophrenia: The Role of Neurocognitive Correlates-A Systematic Review.Brain sciences · 2025Review
- Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological antipsychotic drug interventions represent the cornerstone of the management of patients with schizophrenia and other psychotic spectrum disorders. The choice of the "best" treatment should be made on the basis of several clinical domains. However, despite available treatments, the quality of life reported by patients with schizophrenia taking antipsychotics is still very poor, and this outcome is rarely taken into account in trials assessing the efficacy and effectiveness of antipsychotic treatments. Therefore, we performed a systematic review in order to assess the impact of antipsychotic treatment on patients' quality of life. In particular, we aimed to identify any differences in the improvement in quality of life according to the (a) type of formulation of antipsychotic drugs (i.e., oral vs. depot vs. long-acting injectable); (b) type of the drug (first vs. second vs. third generation); and (c) patients' clinical characteristics. One hundred and eleven papers were included in the review. The main findings were as follows: (1) quality of life is usually considered a secondary outcome in trials on the efficacy and effectiveness of drugs; (2) second-generation antipsychotics have a more positive effect on quality of life; and (3) long-acting injectable antipsychotics are associated with a more stable improvement in quality of life and with a good safety and tolerability profile. Our systematic review confirms that quality of life represents a central element for selecting the appropriate treatment for people with schizophrenia. In particular, the availability of new treatments with a better tolerability profile, a proven effectiveness on patients' cognitive and social functioning, and with a more stable blood concentration might represent the appropriate strategy for improving the quality of life of people with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.